Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ with its lead drug
candidate, lenzilumab™, today announced the appointment of Adrian
Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical
Officer, effective immediately, reporting to Dr. Cameron Durrant,
CEO of Humanigen.
Dr. Kilcoyne brings to Humanigen strong leadership experience
from multinational pharmaceutical and biotechnology companies and a
strong clinical background in both Internal Medicine and Public
Health Medicine. His most recent leadership role was in
AstraZeneca, where he served as Vice President of Oncology Global
Medical Affairs, Head of Evidence Generation and External
Alliances, and previously as Vice President and Head of US Medical
Affairs and Health Economics and Outcomes Research. Dr. Kilcoyne
oversaw the development and delivery of the fully integrated global
evidence strategy across the company’s complete oncology portfolio,
including managing development of real-world evidence,
epidemiology, biostatistics and data sciences, health economics and
outcomes research, payer evidence, medical affairs sponsored
research, and investigator research. He also led Global Oncology
External Alliances, building strong scientific partnerships to
advance patient care.
“Humanigen is delighted to welcome Dr. Kilcoyne,” said Dr.
Durrant. “His experience and knowledge in multiple areas, including
COVID-19, CAR-T and other oncology clinical development areas,
medical affairs, regulatory affairs, evidence generation, health
economics, and partnering gives him a unique insight that can be
leveraged towards Humanigen’s COVID-19, acute GvHD, CAR-T and other
oncology programs with lenzilumab and ifabotuzumab. In addition,
Adrian’s leadership in the external alliances arena will be
instrumental in helping guide the progress of Humanigen’s pipeline
and potential commercialization.”
During his tenure at AstraZeneca, Dr. Kilcoyne oversaw multiple
launches of innovative therapies in oncology, including
acalabrutinib, a Bruton’s tyrosine kinase inhibitor, in the US
(marketed as CALQUENCE®) which has also been investigated in two
Phase 2 studies in COVID-19 patients. Previously, Dr. Kilcoyne held
several leadership positions at Celgene Corporation, a subsidiary
of Bristol Myers Squibb, including Executive Medical Director,
Global Lymphoma Program Lead, Clinical Research and Development
overseeing the development of lenalidomide in Diffuse Large B-Cell
Lymphoma (DLBCL). He was also the US lymphoma CAR-T lead supporting
the clinical development and launch preparation of lisocabtagene
maraleucel (or liso-cel, marketed as Breyanzi®) for the treatment
of adults with relapsed or refractory (R/R) large B-cell lymphoma
after two or more lines of systemic therapy. Prior to this, Dr
Kilcoyne held Medical Affairs and Clinical Development leadership
roles in Sanofi Pasteur MSD, Roche and Eli Lilly.
Dr. Kilcoyne’s responsibilities as Humanigen Chief Medical
Officer include the clinical development and regulatory strategy
for lenzilumab across its varied potential therapeutic indications
including CAR-T, acute GvHD, CMML and COVID-19. Additionally, Dr.
Kilcoyne will be responsible for the clinical development and
regulatory strategy for ifabotuzumab in solid tumors. Dr. Kilcoyne
will also be responsible for medical affairs, real-world evidence
generation, health economics and outcomes and participate in
external alliance evaluation.
“I am excited to join the Humanigen team at this time and look
forward to the opportunity to contribute to the company’s strategic
long-term growth. I am honored to have the opportunity to deliver
on the promise that Humanigen’s innovative portfolio offers to
patients with significant unmet medical need,” said Dr.
Kilcoyne.
Dr. Kilcoyne graduated from Trinity College, Dublin and holds a
MSc in Public Health from the London School of Hygiene and Tropical
Medicine, along with a MSc in Business Administration from the
Warwick Business School. He is the co-author of Pharmaceutical
Medicine, a textbook published by Oxford Specialist Handbooks in
2013, edition 2 now being finalized.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. Humanigen’s immediate focus is on the
development of lenzilumab as a therapy for hospitalized hypoxic
COVID-19 patients. Humanigen recently announced plans to initiate a
randomized, multicenter, potentially registrational, Phase 2 study
to evaluate the efficacy and safety of lenzilumab combined with all
commercially available CD19 CAR-T therapies in diffuse large B-cell
lymphoma. Humanigen is also focused on creating next-generation
combinatory gene-edited CAR-T therapies using strategies to improve
efficacy while employing GM-CSF gene knockout technologies to
control toxicity. In addition, Humanigen is developing its own
portfolio of proprietary first-in-class EphA3-CAR-T for various
solid cancers and EMR1-CAR-T for various eosinophilic disorders.
Humanigen is also exploring the effectiveness of its GM-CSF
neutralization technologies (either through the use of lenzilumab
as a neutralizing antibody or through GM-CSF gene knockout) in
combination with other CAR-T, bispecific or natural killer (NK) T
cell engaging immunotherapy treatments to break the
efficacy/toxicity linkage, including to prevent and/or treat
graft-versus-host disease (GvHD) in patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). For more
information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter and Facebook.
Humanigen Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although Humanigen management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct and
you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding Humanigen’s beliefs relating to
the technologies in Humanigen’s current pipeline.
These forward-looking statements are subject to a number of
risks and uncertainties including, but not limited to, the risks
inherent in Humanigen’s lack of profitability and potential need
for additional capital to grow Humanigen’s business; Humanigen’s
dependence on partners to further the development of Humanigen’s
product candidates; the uncertainties inherent in the development,
attainment of the requisite regulatory approvals or authorization
for emergency or broader patient use for the product candidate and
launch of any new pharmaceutical product; the outcome of pending or
future litigation; and the various risks and uncertainties
described in the "Risk Factors" sections and elsewhere in
Humanigen's periodic and other filings with the Securities and
Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. We
undertake no obligation to revise or update any forward-looking
statements made in this press release to reflect events or
circumstances after the date hereof, to reflect new information or
the occurrence of unanticipated events, to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, in each case, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210421005213/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563 Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024